Please check your internet connection and try again.
## Septran (Co-trimoxazole)
### Overview
Septran is a combination antibiotic containing trimethoprim and sulfamethoxazole.
### Primary Indications
* Urinary tract infections (UTIs)
* Pneumocystis jirovecii pneumonia (PJP) prophylaxis and treatment
* Certain respiratory and gastrointestinal infections
### Adult Dosing
* **UTIs:** 160 mg trimethoprim / 800 mg sulfamethoxazole (1 DS tablet) orally every 12 hours for 3-7 days.
* **PJP Treatment:** 15-20 mg/kg/day of trimethoprim component, divided every 6-8 hours, for 14-21 days.
* **PJP Prophylaxis:** 160 mg trimethoprim / 800 mg sulfamethoxazole (1 DS tablet) orally once daily or 3 times a week.
* Dosing for other indications varies; consult specific guidelines. Maximum daily dose: generally not to exceed 640 mg trimethoprim / 3200 mg sulfamethoxazole.
### Pediatric Dosing
Dosing is based on the trimethoprim component:
* **General Infections:** 8-10 mg/kg/day of trimethoprim, divided every 12 hours.
* **PJP Treatment:** 15-20 mg/kg/day of trimethoprim, divided every 6-8 hours.
* **PJP Prophylaxis:** 5-7.5 mg/kg/day of trimethoprim, divided once or twice daily.
* Dosing should not exceed the adult maximum.
### Dose Adjustments
* **Renal Impairment:**
* CrCl > 30 mL/min: No adjustment needed.
* CrCl 15-30 mL/min: Administer 75% of the usual dose.
* CrCl < 15 mL/min: Avoid use. If unavoidable, administer 50% of the usual dose and monitor drug levels.
### Contraindications
* Known hypersensitivity to trimethoprim, sulfonamides, or any component.
* History of drug-induced immune thrombocytopenia with sulfonamides or trimethoprim.
* Megaloblastic anemia due to folate deficiency.
* Infants < 2 months of age (risk of kernicterus).
* Severe renal or hepatic insufficiency when pharmacokinetic monitoring is not feasible.
### Adverse Effects
Common: Rash, nausea, vomiting, diarrhea, hyperkalemia.
Serious: Severe rash (Stevens-Johnson syndrome, toxic epidermal necrolysis), Stevens-Johnson syndrome, aplastic anemia, agranulocytosis, severe thrombocytopenia, hepatotoxicity, renal failure, hyperkalemia, hypoglycemia.
### Key Drug Interactions
* **Warfarin:** Increased INR. Monitor INR closely.
* **ACE inhibitors, ARBs, Potassium-sparing diuretics:** Increased risk of hyperkalemia.
* **Methotrexate:** Increased methotrexate levels.
* **Potassium supplements:** Increased risk of hyperkalemia.
* **Sulfonylureas:** Potentiated hypoglycemic effect.
### Monitoring
* Renal function (serum creatinine, CrCl)
* Electrolytes (especially potassium)
* Complete blood count (CBC) with differential and platelet count, particularly with prolonged therapy or in immunocompromised patients.
* Liver function tests (LFTs)
* Signs of hypersensitivity reactions.
### Clinical Pearls
* Administer with plenty of fluids to prevent crystalluria.
* May be taken with or without food.
* Sulfonamides can displace bilirubin from albumin; use with caution in jaundiced infants.
* Consider the potential for cross-reactivity in patients with sulfonamide allergies.
***
*This information is intended for healthcare professionals. Always verify current prescribing information and guidelines before use.*
